Phase 2 N=23 Regional TAP Block for Bariatric Patients
Bariatric Surgery · Transverse Abdominal Plane Regional Blocks
Primary: Post Operative Opioid Usage — 2.25; 4 morphine equivalent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=3,573 Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults
Tuberculosis · Tuberculosis Vaccines
Primary: Incident Rates of Definite Pulmonary Tuberculosis (TB) Disease, Not Associated With HIV-infection, Meeting the Case Definition 1 — 0.3; 0.6 cases per 100 person-years…
Phase 2 N=50 Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy
Prostate Cancer
Primary: Changes in Serum Levels of Vitamin D [25(OH)D3] in Subjects in the Supplementation Group and Those in the Control Group (Placebo). — 29.8; 34.8; 46.94; 29.6 ng/ml
Phase 2 N=29 Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Myeloproliferative Diseases
Primary: Number of Patients With Objective Responses (Complete, Major, Moderate or Minor Responses), in Terms of Best Overall Response — 2; 12; 2; 1 Participants
Phase 2 N=58 Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression
Treatment-resistant Depression
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score After 12 Days of Treatment — 21.0; 17.2 units on a scale
Phase 2 N=14 Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
Wet Macular Degeneration · Age-related Macular Degeneration · Diabetic Macular Edema
Primary: Mean Central Subfield Thickness (CST) — 422.9; 419.7; 364.5; 346.7 microns
Phase 2 N=16 A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
Hemophilia A
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) During Advate Treatment Period — 2; 1; 1; 0…
Phase 2 N=130 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
Migraine
Primary: Number of Participants With Headache Response at Two Hours After Initiation of Infusion of Study Drug — 23; 2; 10; 11 Participants — p=1.0000
Phase 2 N=36 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Primary: Median Overall Survival — 13.9 months
Phase 2 N=614 Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Respiratory Symptoms Measured by Evaluating Respiratory Symptoms (E-RS) in COPD. E-RS: COPD Total Score — -2.11; -1.93; -1.47; -0.87 Scores on a…
Phase 2 N=333 Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants) — 63; 62; 3; 5 participants
Phase 2 N=15 Prostate Embolization for Benign Prostatic Hyperplasia
Benign Prostatic Hyperplasia
Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants
Phase 2 N=73 Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients
Indigestion
Primary: Percentage of Participants With Satisfactory Relief of Non-ulcer Dyspepsia Symptoms — 71; 34; 82; 56 percentage of participants
Phase 2 N=54 Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Metastatic Malignant Uveal Melanoma
Primary: Disease Control Rate — 18; 8 Participants
Phase 2 N=100 A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older
Healthy
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) After First Vaccination — 38.7; 20.0 Percentage of participants